| Revenue growth | Q2 consolidated +12.6%; DBF +14.1% |
|---|---|
| Margins | Consol gross margin 74.7% vs 74.5%; DBF GM +134 bps QoQ |
| Demand visibility | Ex-Zorvia Eris growth 17%; all major therapies outgrew market |
Growth
Q2 revenue +12.6% YoY; H1 +12.8%. Adjusted PAT +17.5% in Q2 versus reported PAT +39.2%, which includes exceptional and NCLT-related tax benefits.
Outlook
Further ~100 bps gross margin gain each from Zorvia and Bhopal; full Bhopal shift in H2 next year. No numeric FY guidance given.
Risks
DBF EBITDA margin down 191 bps YoY; ₹36 Cr receivables write-off on at-risk products; Swiss EU CAPA shutdown in Q3.
Investor Presentation filed with BSE, NSE: ERIS. Summary written with AI assistance from the document.
Eris Lifesciences Ltd: key numbers
- Share price
- ₹1,175.40
- Market cap
- ₹16,307 Cr
- Revenue (annual)
- ₹3,129 Cr
- Net profit (annual)
- ₹619.5 Cr
- P/E (TTM)
- 23.1×Sector 46.1×
- Promoter holding
- 54.74%+0.60% QoQ
- FII holding
- 5.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Eris Lifesciences Ltd
All →Eris Lifesciences Q2 FY27 Results: Net Profit ₹187.1 Cr, Up 39.1% YoY
Eris Lifesciences Ltd reported revenue from operations of ₹892.4 Cr (+12.6% YoY) and net profit of ₹187.1 Cr (+39.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹187.1 Cr · +39.1% YoY
Eris Lifesciences Board Meeting Date
Eris Lifesciences has scheduled a board meeting for October 26, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter ending September.
Eris Lifesciences Other Announcement
Eris Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Eris Lifesciences Debt & Borrowing: ₹1,250 Cr
Eris Lifesciences Limited submitted its half-yearly reporting of debt securities for the period ended September 30, 2026. Two tranches of NCDs totaling ₹1,250 Crore remain outstanding.
- Value
- ₹1,250 Cr
Eris Lifesciences Management Change
Eris Lifesciences Limited announced the resignation of Mr. Krishnakumar Vaidyanathan from his roles as Executive Director and Chief Operating Officer. The resignation was effective September 30, 2026.
Eris Lifesciences Annual General Meeting
Eris Lifesciences Limited conducted its 20th Annual General Meeting on September 25, 2026. Shareholders transacted business including the adoption of audited financial statements and director re-appointments.